BACKGROUND:Insulin therapy is most effective when dosage is frequently adjusted. We sought to evaluate the effort required to maintain A1C below 7% once attained in older patients with type 2 diabetes. METHODS: A total of 2380 insulin dosage adjustment episodes were analyzed for their intensity and frequency. The data were divided into an "induction period" (n=608), defined as the time before subjects' A1C dropped below 7% for the first time, and a "maintenance period" (n=1772), defined as the remaining study period. The data originated from a published study and included 26 older subjects with suboptimally controlled type 2 diabetes treated for a year with intensive insulin therapy. To achieve therapy goals, the study team contacted the subjects once every few weeks, reviewed records and optimized the insulin dosage. RESULTS: During both the induction and maintenance periods, insulin dosage (both long-acting and fast-acting) was adjusted by more than 20%. Maintaining A1C below 7% required dosage adjustments every 2.7(±1.0) weeks, averaging 11.4% (±4.0) in 2.0 (±0.3) different components of insulin dosage (i.e., two of either long-acting or short-acting for breakfast, lunch or dinner) per contact. CONCLUSIONS: Considerable effort was required to maintain optimal A1C levels in older patients with type 2 diabetes. Since the full benefit of insulin therapy is attained only when multiple components of insulin dosage are frequently adjusted and given the growing shortage of care providers' availability, innovative approaches are needed to empower patients to safely make their own insulin adjustments. Published by Elsevier Inc.
RCT Entities:
BACKGROUND:Insulin therapy is most effective when dosage is frequently adjusted. We sought to evaluate the effort required to maintain A1C below 7% once attained in older patients with type 2 diabetes. METHODS: A total of 2380 insulin dosage adjustment episodes were analyzed for their intensity and frequency. The data were divided into an "induction period" (n=608), defined as the time before subjects' A1C dropped below 7% for the first time, and a "maintenance period" (n=1772), defined as the remaining study period. The data originated from a published study and included 26 older subjects with suboptimally controlled type 2 diabetes treated for a year with intensive insulin therapy. To achieve therapy goals, the study team contacted the subjects once every few weeks, reviewed records and optimized the insulin dosage. RESULTS: During both the induction and maintenance periods, insulin dosage (both long-acting and fast-acting) was adjusted by more than 20%. Maintaining A1C below 7% required dosage adjustments every 2.7(±1.0) weeks, averaging 11.4% (±4.0) in 2.0 (±0.3) different components of insulin dosage (i.e., two of either long-acting or short-acting for breakfast, lunch or dinner) per contact. CONCLUSIONS: Considerable effort was required to maintain optimal A1C levels in older patients with type 2 diabetes. Since the full benefit of insulin therapy is attained only when multiple components of insulin dosage are frequently adjusted and given the growing shortage of care providers' availability, innovative approaches are needed to empower patients to safely make their own insulin adjustments. Published by Elsevier Inc.
Authors: Richard M Bergenstal; Mary Johnson; Rebecca Passi; Anuj Bhargava; Natalie Young; Davida F Kruger; Eran Bashan; Stanley G Bisgaier; Deanna J Marriott Isaman; Israel Hodish Journal: Lancet Date: 2019-02-23 Impact factor: 79.321
Authors: Richard M Bergenstal; Eran Bashan; Margaret McShane; Mary Johnson; Israel Hodish Journal: Diabetes Technol Ther Date: 2012-05-08 Impact factor: 6.118
Authors: Sara M Andrews; Nina R Sperber; Jennifer M Gierisch; Susanne Danus; Stephanie L Macy; Hayden B Bosworth; David Edelman; Matthew J Crowley Journal: Patient Prefer Adherence Date: 2017-03-03 Impact factor: 2.711
Authors: Afaf Absood; Benjamin Gandomani; Anthony Zaki; Vlad Nasta; Andrew Michail; Peter M W Habib; Israel Hodish Journal: PLoS One Date: 2013-02-07 Impact factor: 3.240
Authors: Elizabeth A Kobe; David Edelman; Phillip E Tarkington; Hayden B Bosworth; Matthew L Maciejewski; Karen Steinhauser; Amy S Jeffreys; Cynthia J Coffman; Valerie A Smith; Elizabeth M Strawbridge; Steven T Szabo; Shivan Desai; Mary P Garrett; Theresa C Wilmot; Teresa J Marcano; Donna L Overby; Glenda A Tisdale; Melissa Durkee; Susan Bullard; Moahad S Dar; Amy C Mundy; Janette Hiner; Sonja K Fredrickson; Nadya T Majette Elliott; Teresa Howard; Deborah H Jeter; Susanne Danus; Matthew J Crowley Journal: Contemp Clin Trials Date: 2020-09-21 Impact factor: 2.226